CINJ 050703: A Phase Ib open-label, two-arm, dose-finding study of E7389 in combination with carboplatin in patients with solid tumours.

Trial Profile

CINJ 050703: A Phase Ib open-label, two-arm, dose-finding study of E7389 in combination with carboplatin in patients with solid tumours.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Carboplatin; Eribulin
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc; Eisai Medical Research
  • Most Recent Events

    • 24 May 2016 According to Eisai media release, data of this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), in June 2016.
    • 13 Jul 2012 Status changed from recruiting to discontinued as reported by Clinical Trials Registry - India.
    • 03 May 2011 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top